Logo image of UNCY

UNICYCIVE THERAPEUTICS INC (UNCY) Stock Price, Quote, News and Overview

NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD

4.64  -0.26 (-5.31%)

After market: 4.67 +0.03 (+0.65%)

UNCY Quote, Performance and Key Statistics

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (7/2/2025, 8:02:30 PM)

After market: 4.67 +0.03 (+0.65%)

4.64

-0.26 (-5.31%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11
52 Week Low2.02
Market Cap559.72M
Shares120.63M
Float114.33M
Yearly Dividend0.01
Dividend YieldN/A
PEN/A
Fwd PE0.57
Earnings (Next)N/A N/A
IPO06-17 2021-06-17


UNCY short term performance overview.The bars show the price performance of UNCY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

UNCY long term performance overview.The bars show the price performance of UNCY in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of UNCY is 4.64 USD. In the past month the price decreased by -39.19%. In the past year, price increased by 1.53%.

UNICYCIVE THERAPEUTICS INC / UNCY Daily stock chart

UNCY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.57 336.94B
AMGN AMGEN INC 14.3 159.62B
GILD GILEAD SCIENCES INC 14.41 138.71B
VRTX VERTEX PHARMACEUTICALS INC N/A 117.37B
REGN REGENERON PHARMACEUTICALS 12.36 59.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 43.00B
ARGX ARGENX SE - ADR 94.8 33.28B
ONC BEONE MEDICINES LTD-ADR 6.24 26.43B
BNTX BIONTECH SE-ADR N/A 26.02B
NTRA NATERA INC N/A 22.06B
BIIB BIOGEN INC 8.42 19.52B
INSM INSMED INC N/A 17.89B

About UNCY

Company Profile

UNCY logo image Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Company Info

UNICYCIVE THERAPEUTICS INC

4300 El Camino Real, Suite 210

Los Altos CALIFORNIA US

CEO: Shalabh Gupta

Employees: 22

UNCY Company Website

UNCY Investor Relations

Phone: 16503840642

UNICYCIVE THERAPEUTICS INC / UNCY FAQ

What is the stock price of UNICYCIVE THERAPEUTICS INC today?

The current stock price of UNCY is 4.64 USD. The price decreased by -5.31% in the last trading session.


What is the ticker symbol for UNICYCIVE THERAPEUTICS INC stock?

The exchange symbol of UNICYCIVE THERAPEUTICS INC is UNCY and it is listed on the Nasdaq exchange.


On which exchange is UNCY stock listed?

UNCY stock is listed on the Nasdaq exchange.


What is UNICYCIVE THERAPEUTICS INC worth?

UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 559.72M USD. This makes UNCY a Small Cap stock.


How many employees does UNICYCIVE THERAPEUTICS INC have?

UNICYCIVE THERAPEUTICS INC (UNCY) currently has 22 employees.


What are the support and resistance levels for UNICYCIVE THERAPEUTICS INC (UNCY) stock?

UNICYCIVE THERAPEUTICS INC (UNCY) has a support level at 6.39 and a resistance level at 7.08. Check the full technical report for a detailed analysis of UNCY support and resistance levels.


Should I buy UNICYCIVE THERAPEUTICS INC (UNCY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does UNICYCIVE THERAPEUTICS INC (UNCY) stock pay dividends?

UNCY does not pay a dividend.


What is the Price/Earnings (PE) ratio of UNICYCIVE THERAPEUTICS INC (UNCY)?

UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.1).


UNCY Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is a bad performer in the overall market: 80.38% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

UNCY Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to UNCY. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UNCY Financial Highlights

Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -5.1. The EPS increased by 59.2% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -119.44%
ROE -509%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%91.8%
Sales Q2Q%N/A
EPS 1Y (TTM)59.2%
Revenue 1Y (TTM)-100%

UNCY Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to UNCY. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners52.5%
Ins Owners5.22%
Short Float %N/A
Short Ratio1.03
Analysts
Analysts83.08
Price TargetN/A
EPS Next Y80.74%
Revenue Next YearN/A